We are live on ! Find out more
KAM

Krensavage Asset Management Portfolio holdings

AUM $256M
1-Year Est. Return 69.63%
This Fund
S&P 500
This Quarter Est. Return
+0.48%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$256M
AUM Growth
-$27.4M
Cap. Flow
-$24.1M
Cap. Flow %
-9.41%
Top 10 Hldgs %
86.89%
Holding
22
New
4
Increased
4
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
EMBC icon
Embecta
EMBC
+$7.66M
2
RARE icon
Ultragenyx Pharmaceutical
RARE
+$5.43M
3
ARDX icon
Ardelyx
ARDX
+$3.31M
4
BIIB icon
Biogen
BIIB
+$1.84M
5
INMD icon
InMode
INMD
+$1.72M

Top Sells

Rank Stock Value
1
AVDL
Avadel Pharmaceuticals
AVDL
+$18.4M
2
CAH icon
Cardinal Health
CAH
+$15.2M
3
BNTX icon
BioNTech
BNTX
+$4.11M
4
UTHR icon
United Therapeutics
UTHR
+$3.49M
5
EXEL icon
Exelixis
EXEL
+$3.35M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
UTHR icon
1
United Therapeutics
UTHR
$25.8B
$50M 19.55%
84,282
-7,000
-8% -$3.49M
ENTA icon
2
Enanta Pharmaceuticals
ENTA
$366M
$36.2M 14.16%
2,866,138
+99,748
+4% +$1.34M
JAZZ icon
3
Jazz Pharmaceuticals
JAZZ
$15.9B
$31.7M 12.41%
167,816
– –
BMRN icon
4
BioMarin Pharmaceuticals
BMRN
$11.6B
$29.6M 11.59%
524,786
– –
EXEL icon
5
Exelixis
EXEL
$13.3B
$17.8M 6.97%
415,693
-77,833
-16% -$3.35M
SNY icon
6
Sanofi
SNY
$103B
$15.6M 6.1%
323,946
– –
SUPN icon
7
Supernus Pharmaceuticals
SUPN
$2.59B
$14.5M 5.67%
280,681
-32,818
-10% -$1.67M
INDV icon
8
Indivior Pharmaceuticals
INDV
$4.73B
$10.3M 4.05%
339,532
– –
RARE icon
9
Ultragenyx Pharmaceutical
RARE
$2.45B
$8.19M 3.2%
390,879
+241,245
+161% +$5.43M
VNDA icon
10
Vanda Pharmaceuticals
VNDA
$307M
$8.16M 3.19%
1,180,388
– –
EMBC icon
11
Embecta
EMBC
$216M
$6.5M 2.54%
+735,340
New +$7.66M
GSK icon
12
GSK
GSK
$104B
$5.34M 2.09%
96,729
– –
BNTX icon
13
BioNTech
BNTX
$22.9B
$5.29M 2.07%
59,523
-40,000
-40% -$4.11M
ALKS icon
14
Alkermes
ALKS
$8.22B
$3.81M 1.49%
107,822
– –
BIIB icon
15
Biogen
BIIB
$30B
$3.67M 1.43%
20,000
+10,000
+100% +$1.84M
REGN icon
16
Regeneron Pharmaceuticals
REGN
$78.5B
$3.09M 1.21%
4,000
– –
ARDX icon
17
Ardelyx
ARDX
$1.22B
$3M 1.17%
+500,000
New +$3.31M
INMD icon
18
InMode
INMD
$870M
$1.65M 0.65%
+120,942
New +$1.72M
EOLS icon
19
Evolus
EOLS
$385M
$649K 0.25%
157,985
+57,985
+58% +$281K
ABT icon
20
Abbott
ABT
$183B
$513K 0.2%
+5,000
New +$565K
AVDL
21
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-855,860
Closed -$18.4M
CAH icon
22
Cardinal Health
CAH
$53.9B
– –
-73,745
Closed -$15.2M

Similar funds

CIA
Corigliano Investment Advisers Raleigh, North Carolina $256M AUM 54.89% 1-Year Est. Return
2
2Xideas Kusnacht, Switzerland $255M AUM 0.46% 1-Year Est. Return
CIM
Caldwell Investment Management Toronto, Ontario, Canada $255M AUM 36.87% 1-Year Est. Return
JFG
Juno Financial Group Richmond, Virginia $255M AUM
PIP
Palisades Investment Partners Santa Monica, California $255M AUM 50.52% 1-Year Est. Return
LRIC
Long Road Investment Counsel Kalamazoo, Michigan $255M AUM 12.85% 1-Year Est. Return
GAMC
Garner Asset Management Corp Plano, Texas $255M AUM 22.93% 1-Year Est. Return
TIA
Tiemann Investment Advisors Menlo Park, California $255M AUM 21.35% 1-Year Est. Return

Krensavage Asset Management's Q1 2026 Portfolio in Review

As of Q1 2026, Krensavage Asset Management held 22 positions worth $256M, down 9.7% from $283M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Krensavage Asset Management withdrew a net $24.1M in Q1 2026, closing 2 positions and reducing 4 holdings. Its most notable exit was Avadel Pharmaceuticals, an estimated $18.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Krensavage Asset Management opened a new position in Embecta worth $6.5M.

  • Krensavage Asset Management's largest Q1 2026 buy was Embecta: 735,340 shares worth $6.5M.
  • Krensavage Asset Management added most to Ultragenyx Pharmaceutical in Q1 2026, an estimated $5.43M increase.
  • Krensavage Asset Management's biggest Q1 2026 reduction was BioNTech, cutting an estimated $4.11M.
  • Krensavage Asset Management fully exited Avadel Pharmaceuticals in Q1 2026, selling an estimated $18.4M.
  • Krensavage Asset Management's ten largest holdings make up 87% of its $256M portfolio in Q1 2026.
  • Krensavage Asset Management opened 4 new positions and closed 2 in Q1 2026.
  • Krensavage Asset Management's portfolio value fell 9.7% quarter-over-quarter to $256M.

Based on Krensavage Asset Management's 13F filing for Q1 2026, filed 15 May 2026.